The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving ...
In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving ...
The real “commercial launch” happens years before launch preparation officially begins. Once Phase III begins, your evidence ...
AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...
Teva's Honestly HD campaign, featuring Will Forte, aims to raise awareness about Huntington's disease through personal ...
The US Department of Health and Human Services (HHS) issued new guidance clarifying how pharmaceutical manufacturers can ...
In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still ...
Public Citizen filed a lawsuit against the Trump administration in the U.S. District Court for the District of Columbia ...
PE: After presenting topline results from Phase 3 trials, what's next for Varegacestat? Siegall: We presented topline data.
Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...
Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% ...
PE: What key learnings did your team learn during launch? Skalicky: Three things come to mind. First, integration beats ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results